{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:46:34Z","timestamp":1795146394551,"version":"4.10.3"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi250740-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with increased risk of diabetic retinopathy (DR) and nonarteritic anterior ischemic optic neuropathy (NAION). The risk of sight-threatening complications associated with GLP-1 RAs is underexamined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250740-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate whether the use of GLP-1 RAs in patients with T2D is associated with the development of DR, NAION, or DR complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250740-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study of adults (aged \u226518 years) with T2D and a recent hemoglobin A\n                      <jats:sub>1c<\/jats:sub>\n                      level of 6.5% or higher was conducted between January 1, 2015, and September 30, 2022, using the TriNetX database. The cohort was divided into 2 groups, adjusted for baseline characteristics through propensity score matching (PSM), based on whether the individuals received prescriptions for a GLP-1 RA. The statistical analysis was conducted on October 10, 2024.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250740-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>At least 2 prescriptions of a GLP-1 RA given 6 months apart.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250740-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Cox proportional hazard regression models were used to evaluate the primary outcome: association between GLP-1 RAs and the risk of incident DR, NAION, or sight-threatening complications over a 2-year follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250740-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After PSM, 185\u202f066 individuals (mean [SD] age, 59.0 [12.5] years; 93 389 females [50.5%]) were prescribed GLP-1 receptor agonists. Use of GLP-1 RAs was associated with an increased incidence of DR (hazard ratio [HR], 1.07; 95% CI, 1.03-1.11), while no statistically significant difference was observed in the risk of NAION (HR, 1.26; 95% CI, 0.94-1.70). In a subgroup analysis of 32\u202f695 patients with preexisting DR, GLP-1 RAs were not associated with progression to proliferative DR (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) but were associated with a lower occurrence of vitreous hemorrhages (HR, 0.74; 95% CI, 0.68-0.80), neovascular glaucoma (HR, 0.78; 95% CI, 0.68-0.88), or blindness (HR, 0.77; 95% CI, 0.73-0.82).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250740-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this cohort study of individuals with T2D, GLP-1 RA use was associated with a modestly increased risk of incident DR; however, fewer patients experienced sight-threatening DR complications, including blindness, even among those with preexisting DR. These findings suggest that all patients with T2D treated with GLP-1 RAs, regardless of preexisting DR, should be regularly screened and monitored for potential complications of T2D.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.26321","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:00:27Z","timestamp":1754924427000},"page":"e2526321","source":"Crossref","is-referenced-by-count":70,"title":["GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes"],"prefix":"10.1001","volume":"8","author":[{"given":"David J.","family":"Ramsey","sequence":"first","affiliation":[{"name":"Division of Ophthalmology, Department of Surgery, UMass Chan\u2013Lahey School of Medicine, Burlington, Massachusetts"},{"name":"Department of Ophthalmology, Tufts University School of Medicine, Boston, Massachusetts"},{"name":"Department of Biomedical Sciences and Disease, New England College of Optometry, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhargav","family":"Makwana","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourbha S.","family":"Dani","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manav","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisha","family":"Panchal","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth","family":"Khadke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tirth","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saint Luke\u2019s Mid America Heart Institute and the University of Missouri, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Ronald Reagan\u2013UCLA (University of California, Los Angeles) Medical Center, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Moynihan","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital Heart and Vascular Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Baylor Scott and White Research Institute, Dallas, Texas"},{"name":"Department of Cardiovascular Medicine, University of Mississippi, Jackson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarju","family":"Ganatra","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital & Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"issue":"9","key":"zoi250740r1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi250740r2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi250740r3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"zoi250740r4","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.ekir.2024.04.028","article-title":"Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial.","volume":"9","author":"Tuttle","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"11","key":"zoi250740r5","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors.","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"key":"zoi250740r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.10.448","article-title":"GLP-1 receptor agonist in nonobese patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction.","author":"Khadke","year":"2024","journal-title":"J Card Fail"},{"issue":"19","key":"zoi250740r7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi250740r8","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022.","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"zoi250740r9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy.","volume":"8","author":"Barkmeier","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"8","key":"zoi250740r10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide.","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"zoi250740r11","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.3390\/jcm13061797","article-title":"Novel antidiabetic drugs and the risk of diabetic retinopathy: a systematic review and meta-analysis of randomized controlled trials.","volume":"13","author":"Malyszczak","year":"2024","journal-title":"J Clin Med"},{"issue":"4","key":"zoi250740r12","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study.","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"issue":"2","key":"zoi250740r14","doi-asserted-by":"publisher","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research.","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"7","key":"zoi250740r15","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2006.10.023","article-title":"Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study.","volume":"114","author":"Varma","year":"2007","journal-title":"Ophthalmology"},{"issue":"10","key":"zoi250740r16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0111320","article-title":"Ten-year cumulative incidence of diabetic retinopathy: the Beijing Eye Study 2001\/2011.","volume":"9","author":"Xu","year":"2014","journal-title":"PLoS One"},{"issue":"13","key":"zoi250740r17","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"9683","key":"zoi250740r18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"zoi250740r19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11).","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi250740r20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10278","key":"zoi250740r21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"zoi250740r22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250740r23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1755-5922.2011.00308.x","article-title":"Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials.","volume":"31","author":"Buehler","year":"2013","journal-title":"Cardiovasc Ther"},{"issue":"5","key":"zoi250740r24","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00417-008-1004-3","article-title":"Protection of exendin-4 analogue in early experimental diabetic retinopathy.","volume":"247","author":"Zhang","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"zoi250740r25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.exer.2014.05.004","article-title":"Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats.","volume":"127","author":"Fan","year":"2014","journal-title":"Exp Eye Res"},{"key":"zoi250740r26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1861940","article-title":"GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway.","volume":"2022","author":"Wei","year":"2022","journal-title":"J Diabetes Res"},{"issue":"3","key":"zoi250740r27","first-page":"171","article-title":"Ischaemic optic neuropathy.","volume":"48","author":"Hayreh","year":"2000","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"zoi250740r28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S2213-8587(18)30128-1","article-title":"Incidence and progression of diabetic retinopathy: a systematic review.","volume":"7","author":"Sabanayagam","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"zoi250740r29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1001\/jamaophthalmol.2022.0052","article-title":"Trends in prevalence and treatment of diabetic macular edema and vision-threatening diabetic retinopathy among Medicare Part B fee-for-service beneficiaries.","volume":"140","author":"Lundeen","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"zoi250740r31","doi-asserted-by":"publisher","first-page":"748","DOI":"10.2337\/dc20-0413","article-title":"Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy.","volume":"44","author":"Wykoff","year":"2021","journal-title":"Diabetes Care"},{"issue":"9","key":"zoi250740r32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1056\/NEJM199908263410907","article-title":"Treatment of diabetic retinopathy.","volume":"341","author":"Ferris","year":"1999","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi250740r33","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.","volume":"120","author":"Brown","year":"2013","journal-title":"Ophthalmology"},{"issue":"6","key":"zoi250740r34","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.2337\/diacare.26.6.1731","article-title":"The prevalence of and factors associated with diabetic retinopathy in the Australian population.","volume":"26","author":"Tapp","year":"2003","journal-title":"Diabetes Care"},{"issue":"5","key":"zoi250740r35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1464-5491.2009.02718.x","article-title":"Long-term impact of retinal screening on significant diabetes-related visual impairment in the working age population.","volume":"26","author":"Arun","year":"2009","journal-title":"Diabet Med"},{"issue":"12","key":"zoi250740r36","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US.","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"5","key":"zoi250740r37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1080\/09286586.2024.2310854","article-title":"Trends in anti-vascular endothelial growth factor original Medicare Part B claims in the United States, 2014-2019.","volume":"31","author":"Desai","year":"2024","journal-title":"Ophthalmic Epidemiol"},{"key":"zoi250740r38","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/PPA.S277676","article-title":"Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States.","volume":"14","author":"Weiss","year":"2020","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"zoi250740r39","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs Medicare advantage, 2016 to 2019.","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi250740r13","unstructured":"TriNetX. Real-world data for the life sciences and healthcare. Accessed January 1, 2025. https:\/\/trinetx.com\/"},{"key":"zoi250740r30","unstructured":"Centers for Disease Control and Prevention. About common eye disorders and diseases. Vision and Eye Health. May 21, 2024. Accessed January 1, 2025. https:\/\/www.cdc.gov\/vision-health\/about-eye-disorders\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837378\/ramsey_2025_oi_250740_1753982857.03439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T15:00:28Z","timestamp":1754924428000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26321","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}